Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three months for the supplemental Biologics License ...
The U.S. Food and Drug Administration has approved the expanded use of Axsome Therapeutics' Auvelity (dextromethorphan ...
Alzheimer's Disease," Cleveland Clinic behavioral neurologist Jagan Pillai, MD, PhD, and host Glenn Campbell continue their ...
Migraine is linked to a 30% lower risk for dementia and a 42% lower risk for Alzheimer’s disease than not having migraine, a ...
Recognizing the signs of mild cognitive impairment meant Di could start treatment earlier to help slow her Alzheimer's ...
Families with rare gene mutations that cause Alzheimer's in middle age are giving scientists a unique window on the disease, ...
Families with rare gene mutations that cause Alzheimer's in middle age are giving scientists a unique window on the disease, ...
AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to ...
Ted Turner was diagnosed with Lewy body dementia years before his death at 87. What to know about the symptoms and treatment ...
The FDA has approved Auvelity for treating agitation in patients with dementia due to Alzheimer’s disease, Axsome ...
Researchers at the Indiana University School of Medicine have developed a new way to read the brain's "energy network ...
A new study identified 3 trajectories for preclinical Alzheimer disease progression, categorizing the condition by projected stability.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results